Obesity and Kidney Disease: What Clinicians Need to Know

Estimates say that chronic kidney disease (CKD) will be the fifth leading cause of death worldwide by 2040 — up from 16th in 2016. Those with expertise in addressing obesity may be well positioned to address this onslaught; it’s suggested that a major reason for these high estimates is the prevalence of obesity. There is often a need to treat obesity and kidney disease simultaneously, so knowledge of both is increasingly important for obesity medicine specialists.

People living with obesity face a lifetime chronic kidney disease risk of 41.0%, compared to 32.5% in those without obesity. Obesity is an important risk factor in multiple conditions that affect kidney health, such as diabetes and hypertension. Obesity is also associated with kidney stones and cancers of the kidneys. Even for patients with advanced kidney disease, obesity possess challenges in their ability to qualify for kidney transplantation.

CKD itself worsens metabolic health and can accelerate weight gain, creating a feedback loop that obesity medicine specialists are well-positioned to interrupt early as well as manage obesity in advanced kidney disease. This article discusses the mechanisms connecting obesity to CKD, how to screen for it in practice, and the treatment options now available.

Key takeaways box

• Obesity is a direct risk factor for chronic kidney disease, with the two sharing a complicated bidirectional relationship, and obesity specialists are in a strong position to identify CKD and intervene early, before a person sees a nephrologist.

• Underlying mechanisms may include adiposopathy, insulin resistance, hyperinsulinemia, lipotoxicity, and RAAS overactivation.

• Recent research suggests potential new treatments for early intervention in CKD in people with obesity, including new indications for existing pharmaceuticals.

Why Obesity Is a Direct Risk Factor for CKD

Obesity is an independent risk factor for CKD. In CKD, the number of functional nephrons decreases, causing a progressive decline in kidney function. Obesity contributes to CKD through multiple simultaneous pathways, including the following.

Glomerular Hyperfiltration and Glomerulopathy

People with obesity can experience glomerular hyperfiltration, in which the glomeruli (the kidney’s filtering units) produce excessive amounts of pro-urine. A 2023 study of 342 people with obesity concluded that the glomerular filtration rate increases with body weight. The researchers proposed several possible mechanisms for this phenomenon and stated that early detection is important for intervening ahead of glomerulopathy.

Glomerulopathy (ORG) is a collective term that includes glomerulomegaly (the abnormal enlargement of glomeruli) and/or focal segmental glomerulosclerosis (scarring of the glomeruli). ORG is considered a type of chronic kidney disease.

Adiposopathy (Sick Fat Disease) and RAAS Overactivation[1]

At a cellular level, obesity can be considered an inflammatory disease, as it predisposes a person to pro-inflammatory states. Adipose tissue contains a range of hormones and proteins, including proinflammatory cytokines. Inflammation in adipose tissue can disrupt the normal function of the kidneys and other organs.

Dysfunctional adipose tissue produces excess leptin and deficient adiponectin. Adiposopathy can manifest in a wide range of metabolic conditions, including glomerulopathy, hyperuricemia, and nephrolithiasis (kidney stones).

Knowledge gaps persist in this area due to the interconnectedness of many pro- and anti-inflammatory signaling processes, particularly in visceral, or white, adipose tissue (WAT). WAT secretes adipokines involved in insulin signaling, glucose uptake, fatty acid oxidation, and other energy-producing and metabolic processes.

The renin-angiotensin-aldosterone system (RAAS) plays a role in CKD, too. It is the system of hormones, proteins, enzymes, and reactions critical for regulating blood pressure. Dysfunctional adipose tissue, particularly visceral fat, contributes to overactivation of the RAAS. This overactivation has adverse effects not only on hypertension but on the kidneys as well. It increases renal sodium and water reabsorption.

Apart from its role in inflammation, visceral fat itself increases intra-abdominal pressure, putting greater demands on organs, including the kidneys, renal veins, lymph vessels, ureters, and renal parenchyma. The strain hinders kidney function and further increases blood pressure. Another result of increased stress on the kidneys is them working harder to filter your blood, which can lead to breakdown and scarring.

Lipotoxicity

The accumulation of lipids results from an imbalance between lipid acquisition and lipid disposal, leading to the accumulation of excess fat, or lipotoxicity. Accumulation in non-adipose tissues, ectopic lipid deposition (ELD), contributes directly to kidney disease. ELD leads to organelle dysfunction, abnormal activation of intracellular signaling pathways, chronic inflammation, and cell death.

Different renal cell types respond differently to lipotoxicity. Research into these cell-type-specific responses is limited, although a 2026 study sought to enumerate them. For example, in PTECs, the most abundant and metabolically active cell type, ELD induces mitochondrial dysfunction, inflammation, oxidative stress, and cell death. Moreover, the effects depend on the specific type of lipid, such as triglycerides, FFAs, ceramides, etc.

Insulin resistance and hyperinsulinemia

Numerous studies have reported the prevalence of insulin resistance (IR) in CKD. Risk factors include inflammation and oxidative stress, adipokine derangements, vitamin D deficiency, metabolic acidosis, anemia, and microbial toxins.

IR and kidney disease share a bidirectional relationship. They tend to progress in tandem, with insulin resistance nearly universal in end-stage kidney failure. Similarly, obesity and insulin resistance often co-occur in a vicious cycle: obesity increases insulin resistance, and insulin resistance increases abdominal fat. As beta cells produce more insulin, hyperinsulinemia occurs, which is significant for the kidneys because they are responsible, along with the liver, for clearing plasma insulin, which forces them to work harder. CKD patients are also at an increased risk of hypoglycemia, which is a complication of hyperinsulinemia

Screening for CKD in Patients with Obesity

The OMA Obesity Algorithm includes a comprehensive metabolic panel (CMP) among its recommended routine labs for patients with obesity. This will include assessing renal function. For those at risk for kidney disease, it further recommends urinalysis to look at microalbumin and creatinine.

Albumin/Creatinine Screening

In measuring kidney function, it is common to look at creatinine, a product of muscle metabolism. However, there is evidence that creatinine-based equations may be misleading when it comes to people with obesity. That is because the higher the muscle mass, the higher the serum creatinine, and people with obesity may have less muscle mass relative to body weight.

With this caveat in mind, the estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) are the standard screening methods, per the International Society of Nephrology. Normal albumin is considered less than 30 mg/g, but the eGFR still considers it as a ratio with creatinine.

KDIGO Guidelines

KDIGO is an international nonprofit based in Belgium, providing clinical guidelines for the evaluation and management of kidney disease. Their guidelines are published in the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. An update is underway as of this writing, specifically to the section on delaying progression of CKD. It will address emerging evidence on SGLT-2 inhibitors, GLP-1-based therapies, and nonsteroidal mineralocorticoid receptor antagonists.

The KDIGO guidelines recommend testing anyone with a BMI of 30 or greater, irrespective of comorbidities. The authors state that early detection, including in people who are asymptomatic, provides an opportunity to intervene earlier.

Their 2024 guideline includes a complete algorithm for assessing risk and screening, which covers options for urinalysis and urine sediment, albumin-to-creatinine ratio, serologic tests, ultrasound, kidney biopsy, and genetic testing. There are no current recommendations on frequency of screening for CKD; however, KDIGO recommends annual screening for people with type 2 diabetes.

Keep in mind, these are international guidelines and do not take into consideration the limits of U.S. health insurance coverage or health disparities in the U.S. population.

Treatment Approaches for Obesity-Related CKD

As a clinician who treats obesity, you operate from an advantage, with the opportunity to influence the progression and outcomes of kidney disease.

While the nephrologist manages the kidneys, the obesity medicine specialist can slow or reverse the driver of injury. As CKD progresses to stages 3-5, there is an opportunity to collaborate with a patient’s nephrologist for more comprehensive care.

Weight Loss as Primary Intervention

The four pillars of obesity treatment can provide some guidance for how to help a particular individual approach weight loss that may benefit their kidney health (among many other health factors). Many of the underlying mechanisms for CKD discussed above can be mediated by losing excess weight.

The exact amount of weight loss required to potentially reduce, or at least postpone, kidney damage is still largely unknown. An important caveat is that, in advanced CKD, weight loss has been associated with higher mortality. Weight loss recommendations should be tailored to each patient, with results monitored closely.

Bariatric Surgery

A study published in 2018 reported a reduction in CKD risk in people who underwent bariatric surgery for obesity, at one and seven years post-surgery. Improvements varied by baseline CKD risk:

• Moderate baseline risk (63% and 53%, respectively)

• High baseline risk (78% and 56%, respectively)

• Very high baseline risk (59% and 23%, respectively)

Conversely, bariatric surgery carries certain risks for people with CKD. These higher short-term risks may be worth the potential long-term benefits. If someone is a candidate for bariatric surgery, the potential outcomes for CKD should be part of the shared decision-making.

Nutrition for CKD

As someone adjusts and/or reduces their nutritional intake in the interest of losing weight, they should keep kidney health in mind. Proper balance is important to maintain a healthy balance of salts and minerals. The National Institute of Diabetes and Digestive and Kidney Diseases recommends avoiding foods high in sodium, potassium, and phosphorus, since diseased kidneys may have a harder time removing these from the body.

Nutritional needs change as CKD progresses. A multidisciplinary approach is recommended, including a renal dietitian.

SGLT-2 Inhibitors

SGLT-2 inhibitors may offer kidney protection as well as manage weight and blood sugar levels. Originally used to treat diabetes, this class of drugs now has clinical evidence for improving kidney and heart health. They reduce glomerular pressure and proteinuria, alleviate mechanical stress on the kidneys, and slow the progression of renal dysfunction. A 2025 study called these protective effects “exceptional.”

The American Diabetes Association Standards of Care in Diabetes recommends that “SGLT-2 inhibitors should be initiated in individuals with eGFR ≥20 mL/min/1.73 m² but can safely continue until kidney failure.”

The CREDENCE trial tested the SGLT-2 inhibitor canagliflozin (Invokana) in people with T2DM and albuminuriaand chronic kidney disease. In this double-blind, randomized trial, the primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 mL per minute per 1.73 m²), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group.

Incretin-Based Therapies

As research continues, GLP-1 receptor agonists, dual agonists, and other incretin-based therapies, more applications are being found. Numerous clinical studies are underway in the U.S. as of this writing to examine this class of drugs in treating kidney diseases.

A 2023 paper suggested that the anti-inflammatory and antioxidant effects of incretin therapies could benefit kidney health. While the authors suggest that further research in this area is warranted, they say, “Evidence continues to build that supports benefits to the heart and kidneys of…tirzepatide.” (Tirzepatide is the dual receptor agonist marketed as Mounjaro and Zepbound.)

The FLOW trial tested semaglutide 1.0 mg (the drug in Wegovy and Ozempic). The 3,352 randomized study participants were evaluated later (median of 3.4 years) for major kidney disease events. The risk was 24% lower in the semaglutide group than in the placebo group. In fact, the trial was stopped early (2023) due to its clear evidence of renal protection. Note that these participants all had type 2 diabetes, so the results may not translate to those without that disease.

Building on this body of research, a 2026 analysis of the SURPASS-CVOT trial assessed major kidney events in people using tirzepatide. Although the purpose of the study was to evaluate cardiovascular outcomes in patients treated with either tirzepatide or dulaglutide (Trulicity), data were collected on the participants’ serum creatinine, cystatin C, and urine albumin-to-creatinine ratio (UACR). Of ~17,000 participants, 2,948 had high-risk chronic kidney disease. After a median follow-up of 4·0 years, the risk of the primary composite kidney outcome in the overall population was 23% lower with tirzepatide than with dulaglutide.

Safety of Incretin-Based Therapies

When treating someone with CKD using a GLP-1 or other incretin therapy, monitor for dehydration. Because the side effects include nausea, vomiting, and diarrhea, it’s important to watch for these, particularly in patients with reduced kidney reserve. There have also been case reports of acute kidney injury in people using GLP-1s.

For a detailed comparison of available weight-loss medications, including side effects, visit our article on weight-loss medications, or review our head-to-head comparison of tirzepatide and semaglutide.

Other Pharmaceutical Interventions

ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers) are both commonly recommended for people with CKD. They help block the effects of RAAS, allowing blood vessels to relax. Current guidelines recommend them to treat CKD, along with glomerular diseases and albuminuria. They can also lower blood pressure.

Finerenone, which goes by the brand name Kerendia, is indicated for treating CKD associated with T2D and was shown to prevent CV events in this patient population. The manufacturer, Bayer, is seeking a label extension that would make it available to people without T2D, following the results of a Phase III study announced in June 2026.

Practical Guidance for the Obesity Medicine Specialist

When treating anyone with obesity, kidney health should be monitored. It makes sense to screen proactively for anyone with BMI ≥30, especially those with family history, hypertension, T2D, or metabolic syndrome. Obesity medicine specialists often see these patients earlier than nephrologists, so that timing could benefit the patient’s long-term prognosis. When a patient does consult a nephrologist, along with a renal dietician or others specializing in kidney health, maintain a collaborative approach to fully support their health journey.

Fortunately, there are multiple pharmaceutical options that may simultaneously address obesity and kidney disease, including SGLT-2 inhibitors, GLP-1 RAs, and dual receptor agonists. Lifestyle modifications and, for eligible patients, bariatric surgery, also carry potential benefits for both. Evaluating each patient’s individual situation, you are in a strong position to make a positive, early difference in someone’s health.

[1]Please note: the team rolled RAAS and inflammation into one section since there is overlap. We recommend that this section be carefully reviewed by a medical professional, as it is really complex. Thank you.

The Bottom Line on Obesity and Kidney Disease

Obesity is a direct, independent cause of CKD, not merely a bystander to diabetes and hypertension. The treatment landscape has shifted meaningfully in recent years, with evolving recommendations for screening and treatment, along with the growing body of knowledge about incretin-based therapies and finerenone.

As someone who practices obesity medicine, you have a strong, evidence-based toolkit from which to approach a person’s kidney health.

OMA provides clinical resources such as the Obesity Algorithm, a peer network, and continuing education programs to support you in navigating complex cases like these. Explore our resources to learn more about the many interrelated health conditions that can co-occur with overweight and obesity.